ALECENSA Drug Use Surveillance

ALECENSA Drug Use Surveillance - ALECENSA Drug Use Surveillance

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061763

Enrollment

100

Registered

2026-06-02

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To confirm the following under actual conditions of use of Alectinib Hydrochloride Capsules (hereinafter, this drug) in ALK fusion gene-positive patients with advanced or recurrent solid tumors Non-small cell lung cancer (NSCLC) and inflammatory myofifibroblastic tumors (IMT): Safety in children (under 16 years old) NSCLC and Non-IMT Solid Carcinomas: Efficacy and Safety

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-small cell lung cancer (NSCLC) and inflammatory myofifibroblastic tumors (IMT): Safety in children (under 16 years old) NSCLC and Non-IMT Solid Carcinomas: Efficacy and Safety

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Efficacy: Response rate based on the attending physician's assessment Safety: Incidence rate of adverse events (by MedDRA PT, by severity, by grade)	—

Countries

Japan

Contacts

Public ContactAyako Murayama

Chugai Pharmaceutical Co. Ltd Safety Science 2 Department

murayamaayk@chugai-pharm.co.jp03-3281-6611

Outcome results